Skip to content

Electrical Impedance Imaging of Patients With Cystic Fibrosis

Electrical Impedance Tomography (EIT): A Non-radiating Functional Imaging for Cystic Fibrosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02524704
Enrollment
44
Registered
2015-08-17
Start date
2015-03-31
Completion date
2016-12-31
Last updated
2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

Cystic fibrosis, Electrical Impedance Tomography

Brief summary

The goal of this feasibility study is to evaluate the ability of Electrical Impedance Tomography (EIT) for providing regional and quantitative information about the extent and nature of bronchial obstruction in patients with cystic fibrosis. It is not being conducted to diagnose, treat, prevent, or cure any kind of disease. In electrical impedance tomography low amplitude, low frequency current is applied on electrodes, and the resulting voltage is measured and used to computed the electrical properties of the interior of the chest as they change in time. The computed properties are used to form an image, which can then be used for monitoring and diagnosis.

Detailed description

The goal of this study is to evaluate the ability of Electrical Impedance Tomography (EIT) hardware and software in patients with cystic fibrosis (CF) for providing regional and quantitative information for identifying regions of obstruction and consolidation, and determine whether these measures will correlate with improvements seen after hospitalized treatment for a pulmonary exacerbation (PE). In particular, EIT will be used to identify regions of obstruction (air trapping) and consolidation comprised of atelectasis and airway occlusion (consequences of mucus plugging) in CF patients, and to determine whether EIT can demonstrate the beneficial effects of antibiotic treatment for CF patients with an acute PE by correlating changes in quantitative EIT measures with clinical measures known to improve following therapy, with patients serving as their own controls. Regional changes in air trapping and consolidation from pre to post treatment as indicated by the EIT images will be calculated, with subjects serving as their own control.

Interventions

DEVICECT scan

Applied only when part of the patient's standard care

Sponsors

Children's Hospital Colorado
CollaboratorOTHER
University of Colorado, Denver
CollaboratorOTHER
Colorado State University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* Between the ages of 2 and 21 years (Groups 1 and 2) * Between the ages of 8 and 21 years (Group 3) * Healthy lungs (Group 1) * Clinical diagnosis of cystic fibrosis (Groups 2 and 3) * Clinically indicated for a pulmonary CT scan or will receive one as part of their routine care (Group 2) * Receiving IV antibiotics for a clinically diagnosed pulmonary exacerbation (Group 3)

Exclusion criteria

* Under age 24 months or over age 21. * No informed consent * Known congenital heart disease, arrythmia, or history of heart failure, admission to the intensive care unit, wearing a pacemaker or other surgical implant. * Pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity for identifying air trapping and consolidation2 yearsThe sensitivity and specificity of EIT for identifying regions of air trapping and consolidation will be assessed using the CT scan as the gold standard

Secondary

MeasureTime frameDescription
Accuracy of the EIT computed spirometry values2 yearsThe accuracy of the spirometry measures computed from EIT images will be assessed by comparing to those from the pulmonary function tests
Correlation of EIT derived measures to patient improvement following IV antibiotics2 yearsChanges in quantitative EIT measures will be correlated with clinical measures known to improve following therapy, patients serving as their own controls.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026